V. Chopra

Empagliflozin in the treatment of heart failure with reduced ejection fraction in addition to background therapies and therapeutic combinations (EMPEROR-Reduced): a post-hoc analysis of a randomised, double-blind trial.

José Miguel Contreras, G. Lip, J. De Sutter, 2021, The lancet. Diabetes & endocrinology.

Clinical characteristics and 30-day outcomes in patients with acute decompensated heart failure: Results from Indian College of Cardiology National Heart Failure Registry (ICCNHFR).

P. Dorairaj, Rabin Chakraborty, Jabir Abdullakutty, 2022, International journal of cardiology.

Heart Failure with Preserved Ejection Fraction: Management Guidelines (From Heart Failure Association of India, Endorsed by Association of Physicians of India).

A. Oomman, M. Tiwaskar, U. Jadhav, 2022, The Journal of the Association of Physicians of India.

CSI position statement on management of heart failure in India

T. Nair, S. Seth, R. Sethi, 2018, Indian heart journal.

Cardiological society of India position statement on COVID-19 and heart failure

S. Harikrishnan, N. N. Khanna, P. Mohanan, 2020, Indian Heart Journal.